Nuvation Bio
↗New York, United States
Nuvation Bio is a commercial-stage biopharmaceutical company focused on developing differentiated and novel therapeutic candidates to tackle some of the greatest unmet needs in oncology. Founded by David Hung, M.D., the former founder and CEO of Medivation (acquired by Pfizer), the company leverages a deep understanding of cancer biology to develop a pipeline of small molecule inhibitors and drug-drug conjugates (DDCs).
In 2024, Nuvation Bio significantly expanded its portfolio through the acquisition of AnHeart Therapeutics, transforming into a late-stage global oncology organization. The company successfully transitioned to a commercial entity in June 2025 following the FDA approval of its lead asset, IBTROZI (taletrectinib), for the treatment of ROS1-positive non-small cell lung cancer (NSCLC).
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$25M-$50M
Founded:2018
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$850M+
Investors:Sagard Healthcare Partners, Decheng Capital, Omega Fund Management, Fidelity Growth Company Fund, Vanguard Group
STOCK
Exchange:NYSE
Ticker:NUVB
Market Cap:$1.66B
PIPELINE
Stage:Commercial
Lead Drug Stage:Approved
Modalities:Small molecule, Drug-Drug Conjugate (DDC), Kinase Inhibitors
Active Trials:8
Trial Phases:Phase 1: 3 | Phase 2: 4 | Phase 3: 1
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:AnHeart Therapeutics Ltd., Nuvation Bio Operating Co., Inc.
Key Partnerships:Innovent Biologics (Commercialization of taletrectinib in Greater China), Nippon Kayaku (Commercialization of taletrectinib in Japan), Sagard Healthcare Partners (Non-dilutive royalty financing)
COMPETITION
Position:Emerging
Competitors:Roche (Entrectinib), Pfizer (Crizotinib, Lorlatinib), Bristol Myers Squibb (Repotrectinib), Turning Point Therapeutics
LEADERSHIP
Key Executives:
David Hung, M.D. - Founder, President & CEO
Philippe Sauvage - Chief Financial Officer
Colleen Sjogren - Chief Commercial Officer
Scientific Founders:David Hung, M.D.
Board Members:David Hung, Kathryn Falberg, Robert Bazemore, Min Cui, Junyuan Jerry Wang
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Nuvation Bio. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.